Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Nephrology

Symptoms, Warning Signs, and Monitoring

At a Glance

MPGN monitoring focuses on symptoms and trends in kidney tests: eGFR, urine protein, serum albumin, and blood pressure. Blood or foamy urine, swelling, falling urine output, breathing trouble, or severe infection signs may require prompt or emergency care.

Living with MPGN or C3G requires careful attention to how you feel and what your lab results are saying. Because these conditions involve your immune system attacking your kidney filters, symptoms can sometimes change quickly. Monitoring is not just about recording numbers; it is about catching changes early enough to adjust your treatment and protect your kidney function [1][2].

Recognizing Common Symptoms

Most people with an MPGN pattern of injury experience one of two clinical “syndromes,” though many people have features of both [3]:

  • Nephritic Syndrome: This is often marked by hematuria (blood in the urine), which can make urine look dark or “cola-colored.” You may also have high blood pressure and a sudden drop in how much urine you produce [4].
  • Nephrotic Syndrome: This occurs when your kidneys leak massive amounts of protein into your urine. This leads to hypoalbuminemia (low protein in your blood) and significant edema (swelling), usually in the legs, ankles, or around the eyes [5][6]. You may also notice your urine looks very foamy or bubbly, like soap suds.

When to Seek Immediate Medical Attention

Certain “red flag” symptoms mean your kidneys or body are under severe stress and require urgent, emergency evaluation. Do not drive yourself or wait for a clinic callback if symptoms are severe:

  • Complement Inhibitor Infection Risk (Meningococcal Warning): If you are taking a complement inhibitor (like pegcetacoplan or iptacopan), you are at elevated risk for life-threatening infections. Go to the emergency room immediately if you develop a high fever, severe headache, stiff neck, extreme sensitivity to light, confusion, or a rapidly spreading rash [7].
  • Sudden Fluid Overload: Rapidly worsening swelling, a sharp decrease in urine output, or feeling short of breath even while resting [8][9].
  • Hypertensive Emergency: A sudden, severe headache, blurred vision, or confusion, alongside markedly elevated blood pressure (ask your doctor for your specific danger threshold, e.g., >180/120) [10].
  • Potential Blood Clot: Severe chest pain or sudden swelling and pain in just one leg [11].

Key Metrics for Long-Term Monitoring

Your nephrologist will use several key tests to track your progress over time:

  1. eGFR (Estimated Glomerular Filtration Rate): This is the best overall measure of your kidney function. It tells you how well your kidneys are cleaning your blood. It is normal for eGFR to fluctuate slightly during acute illness, so trends matter most [12][13].
  2. UPCR (Urine Protein-to-Creatinine Ratio): This test measures how much protein you are losing. It is often preferred over a 24-hour urine collection because it can be done with a single sample [1].
  3. Serum Albumin: This measures the protein levels in your blood. Low levels often explain why you are experiencing swelling [12].
  4. Blood Pressure: Maintaining a stable, healthy blood pressure is one of the most important ways to slow down kidney damage [14].

What Does a ‘Good Response’ Look Like?

Success in treating MPGN and C3G is usually measured by how much you can reduce the protein in your urine. While every patient is different, doctors generally use these as useful prognostic benchmarks:

  • The 50% Rule: A reduction in proteinuria of at least 50% over the first 6 to 12 months of treatment is considered a very meaningful sign that the therapy is working [15][16].
  • The 1-Gram Benchmark: Achieving a protein level below 1 gram per day (or a UPCR below 100 mg/mmol) is strongly associated with better long-term outcomes and a lower risk of kidney failure [2][17].
  • Stable eGFR: While some small fluctuations are normal, the goal is to keep your eGFR from dropping by more than 5 mL/min per year [13][18].

If your labs do not meet these goals, it does not mean your treatment has “failed,” but it is an important prompt to talk with your doctor about whether your treatment plan needs to be adjusted [18].

Common questions in this guide

What symptoms can membranoproliferative glomerulonephritis cause?
MPGN may cause blood in the urine, which can look dark or cola-colored, along with high blood pressure and less urine. If it causes heavy protein loss, the urine may look foamy and swelling can develop in the legs, ankles, or around the eyes.
Which warning signs mean I need emergency care with MPGN?
Seek emergency care for rapidly worsening swelling, very little urine, shortness of breath at rest, severe chest pain, or sudden painful swelling in one leg. If you take a complement inhibitor, fever, severe headache, stiff neck, light sensitivity, confusion, or a rapidly spreading rash may signal a serious infection and need immediate evaluation. A severe headache, blurred vision, or confusion with very high blood pressure is also an emergency.
What tests are used to monitor MPGN?
Your nephrologist may follow eGFR, the urine protein-to-creatinine ratio, serum albumin, and blood pressure. eGFR tracks kidney filtering, the urine protein-to-creatinine ratio estimates protein loss from a single urine sample, albumin helps explain swelling, and blood pressure helps assess kidney stress.
What does a good treatment response look like in MPGN?
Doctors often look for at least a 50% reduction in urine protein during the first 6 to 12 months and protein loss below 1 gram per day, or a urine protein-to-creatinine ratio below 100 mg/mmol. They also want eGFR to remain generally stable; not meeting a benchmark does not automatically mean treatment has failed.
How does eGFR show whether MPGN is getting worse?
eGFR estimates how well the kidneys filter the blood, and small changes can occur during an acute illness. Doctors generally focus on the trend over time and aim to prevent a decline of more than about 5 mL/min per year.
How can I monitor MPGN at home?
Track swelling, urine changes, weight, and home blood pressure as your clinician recommends. Report worsening swelling, a sudden weight increase, less urine, cola-colored or very foamy urine, or blood pressure readings that reach your clinician’s specified threshold.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current 'proteinuria' level (UPCR), and what is our target reduction for the next six months?
  2. 2.Is my current 'eGFR' stable, or has there been a decline that suggests rapidly progressive disease?
  3. 3.Given my medications, what are the specific signs of infection I should look for that require an immediate call to your office or an ER visit?
  4. 4.How often do you want me to monitor my blood pressure at home, and what specific reading should trigger a call to you?
  5. 5.Can we review my latest 'serum albumin' levels to see if my risk of swelling or blood clots is increasing?

References

References (18)
  1. 1

    Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

    Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al.

    Kidney international reports 2025; (10(4)):1223-1236 doi:10.1016/j.ekir.2025.01.024.

    PMID: 40303231
  2. 2

    Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

    Nanchen G, Marasà M, Breno M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):626-640 doi:10.2215/CJN.0000000953.

    PMID: 41433110
  3. 3

    Evaluation of the children with C3 glomerulopathy.

    Pinarbasi AS, Dursun I, Poyrazoglu MH, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2020; (31(1)):79-89 doi:10.4103/1319-2442.279964.

    PMID: 32129200
  4. 4

    C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.

    Ponticelli C, Calatroni M, Moroni G

    Frontiers in medicine 2023; (10()):1289812 doi:10.3389/fmed.2023.1289812.

    PMID: 38076230
  5. 5

    C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

    Ruggenenti P, Daina E, Gennarini A, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2019; (74(2)):224-238 doi:10.1053/j.ajkd.2018.12.046.

    PMID: 30929851
  6. 6

    A rare co-existence of celiac disease and C3 glomerulopathy.

    Ilter A, Oruc M, Sarikaya Kayipmaz S, Parmaksiz E

    Nefrologia 2025; (45(7)):501336 doi:10.1016/j.nefroe.2025.501336.

    PMID: 41005826
  7. 7

    Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.

    Vivarelli M, Bomback AS, Meier M, et al.

    Kidney international reports 2024; (9(1)):64-72 doi:10.1016/j.ekir.2023.10.022.

    PMID: 38312795
  8. 8

    Membranoproliferative Glomerulonephritis due to Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella Endocarditis in a Patient with Cirrhosis: A Case Report.

    Mehta AN, Malchira RR, Mehta K, Nast CC

    Glomerular diseases 2025; (5(1)):431-437 doi:10.1159/000549196.

    PMID: 41321541
  9. 9

    Use of a B-cell depleting regimen for antifactor H autoantibody-mediated membranoproliferative glomerulonephritis in a paediatric patient.

    Henderson S, Ardill R, Reynolds B, Kavanagh D

    BMJ case reports 2022; (15(4)) doi:10.1136/bcr-2021-246281.

    PMID: 35444020
  10. 10

    An Unusual Case of Membranoproliferative Glomerulonephritis: Is the Role of Vaccination in Immune Reactivation a Casual or Causal Effect?

    Rodríguez Tudero C, Martín Arribas A, Dominguez Davalos M, et al.

    Reports (MDPI) 2025; (8(3)) doi:10.3390/reports8030141.

    PMID: 40843883
  11. 11

    Fatal Outcome of Membranoproliferative Glomerulonephritis in a Patient With Hidden Visceral Leishmaniasis.

    Mansoursamaei A, Valikhani M, Rafiee H

    Case reports in infectious diseases 2025; (2025()):3448351 doi:10.1155/crdi/3448351.

    PMID: 40421174
  12. 12

    Predictors of poor kidney outcome in children with C3 glomerulopathy.

    Pınarbaşı AS, Dursun I, Gokce I, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(5)):1195-1205 doi:10.1007/s00467-020-04799-7.

    PMID: 33130981
  13. 13

    Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.

    Ruiz-Cabello JE, Yandian F, Torres IB, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(9)):1593-1605 doi:10.2215/CJN.0000001117.

    PMID: 42462202
  14. 14

    Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

    Nakagawa N, Mizuno M, Kato S, et al.

    PloS one 2021; (16(9)):e0257397 doi:10.1371/journal.pone.0257397.

    PMID: 34520493
  15. 15

    Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Caravaca-Fontán F, Fakhouri F, Licht C, et al.

    Kidney international reports 2026; (11(2)):103671 doi:10.1016/j.ekir.2025.10.028.

    PMID: 41502799
  16. 16

    Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy.

    Caravaca-Fontán F, Díaz-Encarnación M, Cabello V, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(7)):1270-1280 doi:10.1093/ndt/gfab075.

    PMID: 33779754
  17. 17

    Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry.

    Masoud S, Wong K, Pitcher D, et al.

    Kidney international 2025; (108(3)):455-469 doi:10.1016/j.kint.2025.06.003.

    PMID: 40582408
  18. 18

    Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.

    Nester C, Decker DA, Meier M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2024; (19(9)):1201-1208 doi:10.2215/CJN.0000000000000505.

    PMID: 38829708

This page is for informational purposes only and does not constitute medical advice. It can help you track MPGN symptoms and warning signs, but your nephrologist should interpret your lab results and tell you when urgent care is needed.